A single chinstrap penguin (Pygoscelis antarctica), which had moulted at the South Shetland Islands, was subsequently tracked during 120 days at sea in the austral winter using a global location system (geolocation) based on light intensity. The bird moved east along the Scotia Ridge to a point approximately 300 km west of the South Sandwich Islands and approximately 1600 km away from the colony in which it had moulted. It spent more than 60% of its time in open water north of the edge of the pack ice.

Systemic vaccination with the BNT162b2 mRNA vaccine stimulates the humoral response. Our study aimed to compare the intensity of the humoral immune response, measured by SARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBD-neutralizing IgG antibody levels after COVID-19 vaccination versus after SARS-CoV-2 infection. We analyzed 1060 people in the following groups: convalescents; healthy unvaccinated individuals; individuals vaccinated with Comirnaty, AstraZeneca, Moderna, or Johnson & Johnson; and vaccinated SARS-CoV-2 convalescents. The concentrations of SARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBD-neutralizing antibodies were estimated in an oncology hospital laboratory by chemiluminescent immunoassay (CLIA; MAGLUMI). Results: (1) We observed a rise in antibody response in both the SARS-CoV-2 convalescent and COVID-19-vaccinated groups. (2) The levels of all antibody concentrations in vaccinated COVID-19 convalescents were significantly higher. (3) We differentiated asymptomatic SARS-CoV-2 convalescents from the control group. Our analysis suggests that monitoring SARS-CoV-2 IgG antibody concentrations is essential as an indicator of asymptomatic COVID-19 and as a measure of the effectiveness of the humoral response in convalescents and vaccinated people. Considering the time-limited effects of post-SARS-CoV-2 infection recovery or vaccination and the physiological half-life, among other factors, we suggest monitoring IgG antibody levels as a criterion for future vaccination.

Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. The aim of our study was to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneka, Moderna, Johnson&Johnson and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in Bialystok Oncology Center laboratory by chemiluminescent immunoassay- CLIA, MAGLUMI. Results: 1. We observed a raise of antibodies response in both, convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated an asymptomatic SARS CoV-2 convalescents from control group. Based on our analysis we suggest that it is important to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection, and as an equivalent of effectiveness of humoral response in convalescents and vaccinated people. Taking into consideration the time-limited nature of the effects of post infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for next vaccination.

Systemic vaccination with the BNT162b2 mRNA vaccine stimulates the humoral response.Our study aimed to compare the intensity of the humoral immune response, measured bySARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBD neutralizing IgG antibody levels, afterCOVID-19 vaccination versus after SARS-CoV-2 infection. We analyzed 1060 people in thefollowing groups: convalescents, healthy vaccinated individuals, individuals vaccinated withComirnaty, AstraZeneca, Moderna, or Johnson & Johnson, and vaccinated SARS-CoV-2convalescents. The concentrations of SARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBDneutralizing antibodies were estimated in the oncology hospital laboratory bychemiluminescent immunoassay (CLIA; MAGLUMI). Results: (1) We observed a rise inantibody response in both SARS-CoV-2 convalescent and COVID-19-vaccinated groups. (2)The levels of all antibody concentrations in vaccinated COVID-19 convalescents weresignificantly higher. (3) We differentiated asymptomatic SARS-CoV-2 convalescents from thecontrol group. Our analysis suggests that monitoring SARS-CoV-2 IgG antibodyconcentrations is essential as an indicator of asymptomatic COVID-19 and as a measure of theeffectiveness of the humoral response in convalescents and vaccinated people. Considering thetime-limited effects of post-SARS-CoV-2 infection recovery or vaccination and thephysiological half-life, among other factors, we suggest monitoring the IgG antibody level as acriterion for the next vaccination.

Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. The aim of our study was to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneca, Moderna, Johnson&Johnson and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in Bialystok Oncology Center laboratory by chemiluminescent immunoassay- CLIA, MAGLUMI. Results: 1. We observed a raise of antibodies response in both, convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated an asymptomatic SARS CoV-2 convalescents from control group. Based on our analysis we suggest that it is important to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection, and as an equivalent of effectiveness of humoral response in convalescents and vaccinated people. Taking into consideration the time-limited nature of the effects of post infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for next vaccination.